Prohost Biotech
HomeArticlesToday's HighlightsIonis, the FDA and the exaggerated selloff of the firm's stock
Today's Highlights
Premium

Ionis, the FDA and the exaggerated selloff of the firm's stock

A complete response letter (CRL) sent by The Division of Metabolism and Endocrinology Products of the United States’ FDA to Ionis Pharmaceuticals (IONS) and its affiliate Akcea Therapeutics (AKCA) reg...
P

Prohost Biotech

1 min read
3
0

Unlock Premium Content

This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.

Unlimited articles
Expert analysis
Research reports

Tags

Akcea Therapeutics (AKCA)
Ionis Pharmaceuticals Inc (IONS)

Comments (0)

Please sign in to join the discussion

Related Articles

Today's Highlights
Premium

Lilly to acquire Centessa Pharmaceuticals to Advance Treatments for Sleep-Wake Disorders

Eli Lilly & Centessa Pharmaceuticals Story March 31, 2026 /PRNewswire/ -- Eli Lilly and Company ( LLY ) and Centessa Pharmaceuticals plc ( CNTA ) announced a definitive agreement for Lilly to acquire...
P

Prohost Biotech

Mar 31, 2026

1m
85
Today's Highlights
Premium

Biogen: FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Biogen in the NEWS Today,  March 30, 2026, Biogen Inc ( BIIB ) announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by th...
P

Prohost Biotech

Mar 30, 2026

1m
77
Today's Highlights
Premium

Rocket Pharmaceuticals Announced FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I

Rocket Pharmaceuticals in the NEWS March 27, 2026, Rocket Pharmaceuticals ( RCKT ) announced that the U.S. FDA has granted accelerated approval for KRESLADI™ (marnetegragene autotemcel), an autologous...
P

Prohost Biotech

Mar 27, 2026

1m
61